SanegeneBio, a clinical-stage biotechnology company, has secured $55.0 million in new funding from investors. This capital infusion is intended to support the company's ongoing efforts in discovering and developing genetic medicines. SanegeneBio focuses on addressing obesity, cardiometabolic, and autoimmune diseases through its proprietary RNA interference (RNAi) technology.
Founded in 2021 by industry veterans with deep RNAi expertise, SanegeneBio operates with headquarters in Boston and R&D operations spanning both the U.S. and China. The company is developing best-in-class genetic medicines utilizing its proprietary LEAD™ (Ligand and Enhancer Assisted Delivery) technology platform. This platform is designed to enable tissue-specific silencing of disease-driving genes in various cell types, including liver, adipose tissue, muscle, and immune cells, through safe and infrequent subcutaneous dosing.
The $55.0 million in funding is expected to accelerate the advancement of SanegeneBio's clinical pipeline and further enhance its research and development capabilities. The company is committed to leveraging its RNAi expertise to bring transformative therapies to patients globally. This investment underscores the potential of SanegeneBio's approach to address significant unmet medical needs in chronic diseases.
Looking ahead, SanegeneBio plans to continue expanding its scientific endeavors and advancing its therapeutic candidates through clinical development. The company remains focused on its mission to deliver innovative RNAi-based treatments that can make a meaningful impact on patient health and contribute to the evolving landscape of genetic medicine.
